Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S by José A. Fernández, Xiao Xu, Ranjeet K.

Slides:

Advertisements

Similar presentations

Practical of the First and Second Experiments

Advertisements

TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain by Natalia Reglińska-Matveyev, Helena M. Andersson, Suely M. Rezende,

Molecular Mechanism of Antibody-Mediated Activation of β-galactosidase

3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by.

Activation of factor XI by products of prothrombin activation

Roles of RabGEF1/Rabex-5 domains in regulating FcϵRI surface expression and FcϵRI-dependent responses in mast cells by Janet Kalesnikoff, Eon J. Rios,

The cytoprotective protein C pathway

Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.

by Sunghyouk Park, Michael E. Johnson, and Leslie W.-M. Fung

Protein S Gla-domain mutations causing impaired Ca2+-induced phospholipid binding and severe functional protein S deficiency by Suely M. Rezende, David.

Defective release of α granule and lysosome contents from platelets in mouse Hermansky-Pudlak syndrome models by Ronghua Meng, Jie Wu, Dawn C. Harper,

Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants by Andrew Perkins, Xiangmin Xu, Douglas.

Crystal Structure of the Tandem Phosphatase Domains of RPTP LAR

Activation of the Erythropoietin Receptor Is Not Required for Internalization of Bound Erythropoietin by Diana L. Beckman, Lilie L. Lin, Mary E. Quinones,

by Malte Peters, Albrecht M. Müller, and Stefan Rose-John

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII by Kagehiro Amano,

Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface by Hironao Wakabayashi, Fatbardha Varfaj,

by Laurent O. Mosnier, Andrew J

Truman J. Milling, MD, Scott Kaatz, DO, MSc

Alterations in platelet secretion differentially affect thrombosis and hemostasis by Smita Joshi, Meenakshi Banerjee, Jinchao Zhang, Akhil Kesaraju, Irina.

The γ-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding.

by Fabian Stavenuiter, and Laurent O. Mosnier

RNA Ligase Structures Reveal the Basis for RNA Specificity and Conformational Changes that Drive Ligation Forward Jayakrishnan Nandakumar, Stewart Shuman,

by Nuha Shiltagh, John Kirkpatrick, Lisa D. Cabrita, Tom A. J

The common hereditary elliptocytosis-associated α-spectrin L260P mutation perturbs erythrocyte membranes by stabilizing spectrin in the closed dimer conformation.

by Parisa Asvadi, Zohra Ahmadi, and Beng H. Chong

Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.

by Eun-Ju Lee, Daniel J. Dykas, Andrew D. Leavitt, Rodney M

by Andrew J. Gale, Mary J. Heeb, and John H. Griffin

Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity by Gary E. Gilbert, Valerie A. Novakovic,

Volume 11, Issue 9, Pages (May 2001)

A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex by Rinku Majumder, Mary Ann.

Interaction of kindlin-3 and β2-integrins differentially regulates neutrophil recruitment and NET release in mice by Zhen Xu, Jiayi Cai, Juan Gao, Gilbert.

Hierarchical Binding of Cofactors to the AAA ATPase p97

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,

The structure of the GPIb–filamin A complex

by Alexey Dementiev, Abel Silva, Calvin Yee, Zhe Li, Michael T

A novel form of complete IL-12/IL-23 receptor β1 deficiency with cell surface-expressed nonfunctional receptors by Claire Fieschi, Marita Bosticardo, Ludovic.

Volume 3, Issue 5, Pages (May 2013)

Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production by Soe Soe Htwe, Hidenori Wake, Keyue.

Berislav V. Zlokovic, John H. Griffin Trends in Neurosciences

Volume 97, Issue 6, Pages e4 (March 2018)

by Anant A. Agrawal, Michael Seiler, Lindsey T

Influence of Protein Scaffold on Side-Chain Transfer Free Energies

Volume 16, Issue 4, Pages (April 2009)

A Solution to Limited Genomic Capacity: Using Adaptable Binding Surfaces to Assemble the Functional HIV Rev Oligomer on RNA Matthew D. Daugherty, Iván.

Diabetes Mutations Delineate an Atypical POU Domain in HNF-1α

Volume 89, Issue 5, Pages (May 1997)

Yanhui Xu, Yu Chen, Ping Zhang, Philip D. Jeffrey, Yigong Shi

Fiber-Dependent and -Independent Toxicity of Islet Amyloid Polypeptide

by Changjie Zhang, Anju Kelkar, and Sriram Neelamegham

Volume 21, Issue 2, Pages (February 2014)

Characterization of Tfrc-mutant mice with microcytic phenotypes

Berislav V. Zlokovic, John H. Griffin Trends in Neurosciences

Volume 22, Issue 12, Pages (December 2014)

Volume 15, Issue 1, Pages 5-11 (January 2008)

by Megan S. Rost, Ilya Shestopalov, Yang Liu, Andy H. Vo, Catherine E

Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes by Edward N. van den Brink, Ellen A. M. Turenhout,

by Guojie Wu, Blake A. Mazzitelli, Adam J. Quek, Matthew J

Calpain cleaves phospholipid flippase ATP8A1 during apoptosis in platelets by Weidong Jing, Mehmet Yabas, Angelika Bröer, Lucy Coupland, Elizabeth E. Gardiner,

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera by Richard B. Pouw, Mieke C. Brouwer,

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.

Structure and Dynamics of Zymogen Human Blood Coagulation Factor X

Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products by Wojciech Jankowski, Yara Park, Joseph.

Molecular Mechanism of Antibody-Mediated Activation of β-galactosidase

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites by Katrin J. Czogalla, Kerstin Liphardt,

Y. Zenmei Ohkubo, Emad Tajkhorshid Structure

MSLN-targeted RITs in TNBC in vitro.

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state by Jeremy P. Wood, Lisa M.

by Fabian C. Verbij, Nicoletta Sorvillo, Paul H. P

Presentation transcript:

Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S by José A. Fernández, Xiao Xu, Ranjeet K. Sinha, Laurent O. Mosnier, Michel F. Sanner, and John H. Griffin BloodAdv Volume 1(18):1423-1426 August 8, 2017 © 2017 by The American Society of Hematology

José A. Fernández et al. Blood Adv 2017;1:1423-1426 © 2017 by The American Society of Hematology

Determination of protein S enhancement of anticoagulant activity of APC variants compared with wt-APC. Determination of protein S enhancement of anticoagulant activity of APC variants compared with wt-APC. (A) APC variants dose response prolongation of clotting time using normal human plasma (solid line) and protein S–depleted plasma (dashed line) in FXa-1–stage assays. wt-APC (●) was compared with GED-APC (▲) and APC-del/5 (□). (B) The anticoagulant activity of wt-APC and APC variants was determined in normal plasma (solid bars) and in protein S–depleted plasma (open bars) using FXa-1–stage assays where percent activity was calculated based on wt-APC having 100% activity. (C) The ability of protein S to enhance APC anticoagulant activity was studied using FXa-1–stage assays and using protein S–depleted plasma supplemented with varying concentrations of purified plasma-derived protein S. (D) Mutant APCs or wt-APC were incubated with wt-EPCR/SEAP-wt-PAR-1 cells or wt-EPCR/SEAP-R41Q-PAR-1 cells in Hanks balanced salt solution supplemented with 1.3 mM CaCl2, 0.6 mM MgCl2, and 0.1% bovine serum albumin. After 60 minutes, SEAP release was determined using 1-step p-nitrophenyl phosphate. After correction for background activity in the absence of protease, values were expressed as percentage of the total SEAP activity present on the cells. José A. Fernández et al. Blood Adv 2017;1:1423-1426 © 2017 by The American Society of Hematology

The protein S binding site on APC The protein S binding site on APC. APC is depicted with its membrane-binding GLA domain on the bottom followed upward by EGF1, EGF2, and protease domains. The protein S binding site on APC. APC is depicted with its membrane-binding GLA domain on the bottom followed upward by EGF1, EGF2, and protease domains. (A) The gray oval outlines the protein S binding surface containing 5 labeled amino acid residues (green) whose mutations reduce protein S enhancement of APC’s anticoagulant activity. This surface is on the side opposite from the catalytic triad. (B) When the model in panel A is rotated 180 degrees, the active site triad is visualized on top in red; this surface in panel B lacks residues L38, K43, I73, F95, and W115. Surfaces show Arg87 (purple) whose mutation does not affect protein S cofactor activity. (Images were created using the Python Molecular Viewer v.1.5.6, and the molecular surface was computed using the Maximal Speed Molecular Surface program.17,18)‏ José A. Fernández et al. Blood Adv 2017;1:1423-1426 © 2017 by The American Society of Hematology